Effect of the management of class I obesity with metformin on metalloproteinase activity in patients with chronic periodontitis.

Effect of the management of class I obesity with metformin on metalloproteinase activity in patients with chronic periodontitis.

Nutrición Hospitalaria, October 2019

31516010

Carlos Alberto Zúñiga Curz, Claudia C Calzada Mendoza, Iris Danae Miranda Mondragón, Alfonso Bustamante Bacame, Javier Portilla Robertson, Esther Ocharán Hernández

in Mexico the main problem in public health is obesity and other diseases that are associated whit this condition, including oral health. to evaluate the effect of metformin treatment in patients with class I obese on the activity of metalloproteinases present in periodontium with chronic periodontitis. a clinical study was conducted in 68 patients with class I obesity and periodontal disease. They were divided into 4 groups. 2 of them, in addition to the periodontal treatment, were administered metformin 850 mg per day for six weeks; 2 samples were taken per patient of periodontal tissue before and after each treatment, body mass index, plaque index and inflammation were measured. Acrylamide gel zymography was used to measure the activity of metalloproteinases in the sample of tissue collected. The data obtained were analyzed by descriptive statistics, student t for related samples and one-way ANOVA was performed considering p < 0.01 as statistically significant. in the group of patients who were administered metformin at the end of the treatment, there was a decrease in the body mass index, the degree of inflammation and lower metalloproteinase activity, compared with the control group (65% vs 25%; < 0.01). treatment with metformin in patients with obesity class I and periodontal disease decreases BMI, improves the symptoms of chronic periodontitis and decreases the activity of metalloproteinases 1, 3, 8, V present in periodontium of these patients.